Open AccessThe role of endotheliitis in COVID‐19: Real‐world experience of 11 190 patients and literature review for a pathophysiological map to clinical categorisation
Author(s) -
Dirican Adem,
Ildir Selin,
Uzar Tugce,
Karaman Irem,
Ozkaya Sevket
Publication year - 2021
Publication title -
international journal of clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.756
H-Index - 98
eISSN - 1742-1241
pISSN - 1368-5031
DOI - 10.1111/ijcp.14843
Subject(s) - medicine , intensive care unit , respiratory distress , pneumonia , retrospective cohort study , pediatrics , lung , intensive care medicine , surgery
Abstract Objective COVID‐19 may yield a variety of clinical pictures, differing from pneumonitis to Acute Respiratory Distress Syndrome along with vascular damage in the lung tissue, named endotheliitis . To date, no specific treatment strategy was approved for the prevention or treatment of COVID‐19 in terms of endotheliitis‐related comorbidities. Here, we presented our treatment strategies for 11 190 COVID‐19 patients depending on categorisation by the severity of both the respiratory and vascular distress and presented the manifestations of endotheliitis in skin, lung and brain tissues according to the different phases of COVID‐19. Methods After a retrospective examination, patients were divided into three groups according to their repercussions of vascular distress, which were represented by radiological, histopathological and clinical findings. We presented the characteristics and courses of seven representative and complicated cases which demonstrate different phases of the disease and discussed the treatment strategies in each group. Results Among 11 190 patients, 9294 patients met the criteria for Group A, and 1376 patients were presented to our clinics with Group B characteristics. Among these patients, 1896 individuals (Group B and Group C) were hospitalised. While 1220 inpatients were hospitalised within the first 10 days after the diagnosis, 676 of them were worsened and hospitalised 10 days after their diagnosis. Among hospitalised patients, 520 of them did not respond to group A and B treatments and developed hypoxemic respiratory failure (Group C) and 146 individuals needed ventilator support and were followed in the intensive care unit, and 43 (2.2%) patients died. Conclusion Distinctive manifestations in each COVID‐19 patient, including non‐respiratory conditions in the acute phase and the emerging risk of long‐lasting complications, suggest that COVID‐19 has endotheliitis ‐centred thrombo‐inflammatory pathophysiology. Daily evaluation of clinical, laboratory and radiological findings of patients and deciding appropriate pathophysiological treatment would help to reduce the mortality rate of COVID‐19.